Plain-English translation of NCT06653322 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new drug called SHR-1703 to see if it works better for people with a specific type of asthma called eosinophilic asthma—a type where certain white blood cells called eosinophils are higher than normal and make asthma harder to control. Researchers want to know if this medication can help people whose asthma hasn't gotten better even with strong standard asthma medications. About 400 people will participate, and half will get the new medication while half will get a placebo (a dummy pill with no medicine) to compare results fairly.
Many people with eosinophilic asthma continue to have symptoms and serious flare-ups even when taking high doses of standard asthma treatments. This trial exists to see if this medication could be a better option for these patients who aren't adequately controlled by current therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive SHR-1703 or a placebo, and neither you nor the researchers will know which one you're getting at first. You'll attend multiple visits at a hospital or clinic where they'll check your lung function, take blood tests, monitor your asthma symptoms, and track any side effects. Throughout the study, you'll use a daily app or diary to record how your asthma is doing. The study involves visits at several locations and careful follow-up to see how well the medication works compared to placebo.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment target
~400 participants
Started
November 2024
Primary completion
September 2027
Age range
12 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaopeng Wang
Guangdong Hengrui Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.